CN112190772A - Anastomosis nail with anti-inflammation function and preparation method thereof - Google Patents
Anastomosis nail with anti-inflammation function and preparation method thereof Download PDFInfo
- Publication number
- CN112190772A CN112190772A CN202011083694.1A CN202011083694A CN112190772A CN 112190772 A CN112190772 A CN 112190772A CN 202011083694 A CN202011083694 A CN 202011083694A CN 112190772 A CN112190772 A CN 112190772A
- Authority
- CN
- China
- Prior art keywords
- anastomosis nail
- inflammatory
- dexamethasone
- nail
- anastomosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/73—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals characterised by the process
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/78—Pretreatment of the material to be coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Abstract
The invention discloses an anastomosis nail with an anti-inflammatory function and a preparation method thereof, wherein a pH-responsive anti-inflammatory agent release layer is coupled on the surface of the anastomosis nail; the preparation method comprises the following steps: carrying out surface hydroxylation treatment on the anastomosis nail by using a plasma surface treatment instrument; then carrying out surface hydrazide treatment on the inosculated surface; and finally, soaking the anastomosis nail with the surface hydrazide group in an ethanol solution containing excessive dexamethasone to prepare the anastomosis nail with the anti-inflammatory function. The anastomosis nail with the anti-inflammatory function provided by the invention does not change the mechanical property, but can release dexamethasone on an inflammation part when inflammation occurs after operation due to the fact that the surface of the anastomosis nail is modified with anti-inflammatory drugs such as dexamethasone through a hydrazone bond, so that the effect of diminishing inflammation in time is achieved, the effect of the anastomosis nail is far higher than that of oral administration and injection of the anti-inflammatory drugs, systemic side effects are not caused, and the life quality of a patient is improved.
Description
Technical Field
The invention relates to an anastomat, in particular to an anastomosis nail containing dexamethasone and having an anti-inflammatory function and a preparation method thereof.
Background
As a modern medical instrument for replacing the traditional manual suture, the anastomat has the advantages of reliable quality, convenient use, tightness, proper tightness, rapid suture, few side effects and operation complications and the like, and is popular and advocated for clinical surgeons. However, the incision and the suture can cause inflammation due to trauma, and particularly in circumcision, the incision and the suture can cause great trouble to patients. Research shows that when inflammation occurs, catabolism of three nutrients in inflammation area is enhanced, and H in inflammation position+The rapid increase leads to the rapid decrease of pH, and the drugs such as dexamethasone and the like are taken as glucocorticoid drugs, can prevent the synthesis and release of inflammation mediators, and have obvious antibacterial and anti-inflammatory effects, so that the modification of the anti-inflammatory drugs (such as dexamethasone) on the surface of the anastomosis nail becomes a new research direction for improving the applicability of the anastomat.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to provide an anastomosis nail which can quickly release anti-inflammatory drugs when inflammation appears after cutting and suturing; the second purpose of the invention is to provide a preparation method of the staple.
The technical scheme is as follows: the anastomosis nail with the anti-inflammatory function is provided with a pH-responsive anti-inflammatory agent release layer coupled to the surface of the anastomosis nail.
Further, the anti-inflammatory agent release layer is formed by connecting dexamethasone to the surface of the anastomosis nail through a hydrazone bond, and the pH response range is 5.6-6.5. The hydrazone bond (-CO-NH-N ═ has acid response capacity, and can be rapidly decomposed in an environment with the pH value of 5.6-6.5, so that dexamethasone covalently connected with the hydrazone bond is rapidly released, the anastomosis nail can rapidly release anti-inflammatory drugs when inflammation occurs, and the inflammation is relieved, and the anti-inflammatory drugs can be dexamethasone or other drugs containing carbonyl and having an anti-inflammatory function.
The invention also provides a preparation method of the anastomosis nail with the anti-inflammation function, which comprises the following steps:
firstly, carrying out surface hydroxylation treatment on the anastomosis nail by adopting plasma equipment;
soaking the hydroxylated anastomosis nail in a saturated acetone solution of 3-aminopropyltriethoxysilane, heating to 60-85 ℃, reacting for 20-30 h, and cleaning and drying by using ethanol after the reaction is finished;
step three, respectively dissolving oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, soaking the anastomosis nail treated in the step two in the mixed solution, reacting at room temperature for 20-30 h, cleaning by using deionized water after the reaction is finished, and drying
Step four, respectively dissolving hydrazine hydrate, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, soaking the anastomosis nail treated in the step three in the mixed solution, reacting at room temperature for 20-30 h, and cleaning and drying the anastomosis nail by using deionized water after the reaction is finished to obtain the surface hydrazide-based anastomosis nail;
and step five, soaking the anastomosis nail with the surface hydrazide group in an ethanol solution containing dexamethasone, reacting for 20-30 h at 60-70 ℃, washing with ethanol after the reaction, and drying to obtain the anastomosis nail with the anti-inflammatory function.
In the scheme, a new functional group is introduced on the surface of a material by inserting a chemical functional group by adopting a plasma surface treatment technology, so that hydroxyl is introduced on the surface of the anastomosis nail for chemical modification, the introduced hydroxyl can activate the surface of the anastomosis nail and is beneficial to the introduction of subsequent functional groups, after the surface of the anastomosis nail is subjected to hydroxylation treatment, the anastomosis nail is soaked in a saturated acetone solution of 3-aminopropyltriethoxysilane, and the hydroxyl on the surface of the anastomosis nail and an ethoxy group in the 3-aminopropyltriethoxysilane react with each other to ensure that an internal amino group (C-NH) of the 3-aminopropyltriethoxysilane is reacted2) Exposed on the surface of the staple, containing ammoniaProviding an active site for subsequent functionalization, further soaking the treated anastomosis nail in an aqueous solution containing oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), reacting and combining surface-exposed internal amino groups with carboxyl groups of the oxalic acid under the combined action of EDC and NHS, so that the carboxyl groups are exposed on the surface of the anastomosis nail, wherein the surface carboxylation is a basis for forming hydrazone bonds with acid response functions, then soaking the anastomosis nail in an aqueous solution containing hydrazine hydrate, EDC and NHS, and reacting the surface-exposed carboxyl groups with the hydrazine hydrate to form-CO-NH2Completing the hydrazidation of the surface of the anastomosis nail, finally reacting the hydrazidated anastomosis nail with dexamethasone, and reacting the dexamethasone with-CO-NH2The reaction forms a hydrazone bond (-CO-NH-N ═) structure which has acid response capability and can decompose and release dexamethasone linked with the hydrazone structure under a specific pH environment.
Further, in the fifth step, the ethanol solution containing dexamethasone is specifically prepared as follows: adding 20-100 g of dexamethasone into each 10mL of ethanol solution
Further, in the third step, the molar ratio of oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide is 1: (0.8-1.2): (0.8 to 1.2).
Further, in the fourth step, the hydrazine hydrate, the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and the N-hydroxysuccinimide are prepared in a molar ratio of 1: (0.8-1.2): (0.8 to 1.2).
Further, in the first step, the processing power of the plasma equipment is 1-5 kw, the processing time is 10-30 min, the processing temperature is 0-40 ℃, and oxygen is used as the processing atmosphere to perform processing under the vacuum condition.
Has the advantages that: compared with the prior art, the invention has the following remarkable advantages: the anastomosis nail with the anti-inflammatory function provided by the invention does not change the mechanical property, but can release dexamethasone on an inflammation part when inflammation occurs after operation due to the fact that the surface of the anastomosis nail is modified with anti-inflammatory drugs such as dexamethasone through a hydrazone bond, so that the effect of diminishing inflammation in time is achieved, the effect of the anastomosis nail is far higher than that of oral administration and injection of the anti-inflammatory drugs, systemic side effects are not caused, and the life quality of a patient is improved.
Drawings
FIG. 1 is a graph of the release rate of dexamethasone over time for staples prepared in example 1 in solutions of different pH;
FIG. 2 is a graph showing the change in the number of leukocytes and neutrophils in the blood of a mouse.
Detailed Description
The invention is further illustrated by the following figures and examples.
Example 1
(1) Surface hydroxylation of staples
Placing the anastomosis nail in an EPT-02 plasma surface treatment instrument, controlling the temperature at 25 ℃, the power at 2.5kw, the time at 20min, wherein the treatment atmosphere is vacuum, and the plasma is oxygen plasma, and performing surface hydroxylation treatment on the anastomosis nail;
(2) surface hydrazide alkylation of anastomosis nail
Firstly, soaking the surface-hydroxylated anastomosis nail in a saturated acetone solution of 3-aminopropyltriethoxysilane, heating to 65 ℃, reacting for 24 hours, and cleaning and drying by using ethanol after the reaction is finished; then dissolving oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, wherein the molar ratio of the oxalic acid to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride to the N-hydroxysuccinimide is 1:1:1, soaking the treated anastomosis nail in the mixed solution, reacting for 24 hours at room temperature, washing and drying by using deionized water, and keeping the room temperature at 25 ℃; finally, dissolving hydrazine hydrate, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, wherein the molar ratio of the hydrazine hydrate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride to the N-hydroxysuccinimide is 1:1:1, soaking the anastomosis nail in the mixed solution, reacting for 24 hours at room temperature, washing and drying by using deionized water, and finishing surface hydrazide alkylation of the anastomosis nail at the room temperature of 25 ℃;
(3) anastomosis nail with anti-inflammation function
The method comprises the following steps of soaking the surface hydrazide-based anastomosis nail in an ethanol solution containing excessive dexamethasone (Dex), specifically preparing the anastomosis nail by adding 30g of dexamethasone into 10mL of the ethanol solution, then reacting at 65 ℃ for 24h to ensure that the hydrazide group on the surface of the titanium nail fully reacts with the dexamethasone, and after the reaction, washing with ethanol and drying.
See the following schematic procedure for specific preparation:
example 2
(1) Surface hydroxylation of staples
Placing the anastomosis nail in an EPT-02 plasma surface treatment instrument, controlling the temperature at 40 ℃, the power at 4kw, the time at 30min, and carrying out surface hydroxylation treatment on the anastomosis nail, wherein the treatment atmosphere is vacuum and the plasma is oxygen plasma;
(2) surface hydrazide alkylation of anastomosis nail
Firstly, soaking the surface-hydroxylated anastomosis nail in a saturated acetone solution of 3-aminopropyltriethoxysilane, heating to 70 ℃, reacting for 20 hours, and cleaning and drying by using ethanol after the reaction is finished; then dissolving oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, wherein the molar ratio of the oxalic acid to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride to the N-hydroxysuccinimide is 1:1.2:0.8, soaking the treated anastomosis nail in the mixed solution again, reacting for 20 hours at room temperature, washing and drying by using deionized water, and keeping the room temperature at 25 ℃; finally, dissolving hydrazine hydrate, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, wherein the molar ratio of the hydrazine hydrate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride to the N-hydroxysuccinimide is 1:1.2:0.8, placing the anastomosis nail in the mixed solution for soaking, reacting for 20 hours at room temperature, washing and drying by using deionized water, and finishing surface hydrazide alkylation of the anastomosis nail at the room temperature of 25 ℃;
(3) anastomosis nail with anti-inflammation function
The method comprises the following steps of soaking the surface hydrazide-based anastomosis nail in an ethanol solution containing excessive dexamethasone (Dex), specifically preparing the anastomosis nail by adding 100mg of dexamethasone into 10mL of the ethanol solution, then reacting at 60 ℃ for 20h to ensure that the hydrazide group on the surface of the titanium nail fully reacts with the dexamethasone, and after the reaction, washing with ethanol and drying.
Example 3
(1) Surface hydroxylation of staples
Placing the anastomosis nail in an EPT-02 plasma surface treatment instrument, controlling the temperature at 10 ℃, the power at 5kw, the time at 40min, wherein the treatment atmosphere is vacuum, and the plasma is oxygen plasma, and performing surface hydroxylation treatment on the anastomosis nail;
(2) surface hydrazide alkylation of anastomosis nail
Firstly, soaking the surface-hydroxylated anastomosis nail in a saturated acetone solution of 3-aminopropyltriethoxysilane, heating to 80 ℃, reacting for 30 hours, and cleaning and drying by using ethanol after the reaction is finished; then dissolving oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, wherein the molar ratio of the oxalic acid to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride to the N-hydroxysuccinimide is 1:0.8:1, soaking the treated anastomosis nail in the mixed solution again, reacting for 30 hours at room temperature, washing and drying by using deionized water, and keeping the room temperature at 25 ℃; finally, dissolving hydrazine hydrate, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, wherein the molar ratio of the hydrazine hydrate to the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride to the N-hydroxysuccinimide is 1:0.8:1, soaking the anastomosis nail in the mixed solution, reacting for 30 hours at room temperature, washing and drying by using deionized water, and finishing surface hydrazide acylation of the anastomosis nail at the room temperature of 25 ℃;
(3) anastomosis nail with anti-inflammation function
The method comprises the following steps of soaking the surface hydrazide-based anastomosis nail in an ethanol solution containing excessive dexamethasone (Dex), specifically preparing the anastomosis nail by adding 50mg of dexamethasone into 10mL of the ethanol solution, then reacting at 70 ℃ for 30h to ensure that the hydrazide group on the surface of the titanium nail fully reacts with the dexamethasone, and after the reaction, washing with ethanol and drying.
Example 4
Two portions of the dexamethasone-modified staples, prepared as described in example 1 above, were taken, one portion soaked in 50mL of Phosphate Buffered Saline (PBS) at pH 7.3 and one portion soaked in 50mL of PBS at pH 6.5, and placed on a constant temperature shaker at 37 ℃. The absorption intensity at 240nm was measured for 100. mu.L of the solution at 0, 0.5, 1, 2, 4, 7, 12, and 24 hours, respectively. According to a standard curve of the relation between the dexamethasone concentration determined in advance and the absorption intensity of the dexamethasone at 240nm, the amount of dexamethasone released at different time points is obtained. As shown in FIG. 1, dexamethasone was slowly released in PBS 7.3, but rapidly released in PBS 6.5 due to cleavage of the hydrazone bond. This result demonstrates that the staples having anti-inflammatory function can be prepared by the method of example 1, and release dexamethasone very slowly and without affecting blood concentration when inflammation does not occur, and can rapidly release dexamethasone in situ when inflammation occurs, thereby inhibiting inflammatory reaction and alleviating pain of patients.
Example 5
10 inflammation model mice were randomly divided into two groups, the first group of mice implanted with two untreated staples each, and the second group of mice implanted with two staples treated in example 1 each. After 7 days, the mice were sacrificed and their blood was taken using an anticoagulation tube and examined for changes in the number of leukocytes and neutrophils in the blood. As shown in fig. 2, the amount of White Blood Cells (WBC) and Neutrophils (NEUT) increased when the mice developed inflammation, while the amount of white blood cells and neutrophils decreased significantly after implantation of the staples treated in example 1 in the second group of mice, approaching normal levels, indicating that inflammation was inhibited, thus indicating that the staples prepared in example 1 had the effect of inhibiting inflammation.
Claims (7)
1. An anastomosis nail with anti-inflammation function is characterized in that: the surface of the anastomosis nail is coupled with a pH-responsive anti-inflammatory agent release layer.
2. The anti-inflammatory staple according to claim 1, wherein: the anti-inflammatory agent release layer is formed by connecting dexamethasone to the surface of the anastomosis nail through a hydrazone bond, and the pH response range is 5.6-6.5.
3. A method for preparing a staple having an anti-inflammatory function according to claim 1 or 2, comprising the steps of:
firstly, carrying out surface hydroxylation treatment on the anastomosis nail by adopting plasma equipment;
soaking the hydroxylated anastomosis nail in a saturated acetone solution of 3-aminopropyltriethoxysilane, heating to 60-85 ℃, reacting for 20-30 h, and cleaning and drying by using ethanol after the reaction is finished;
dissolving oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, soaking the anastomosis nail treated in the step two in the mixed solution, reacting at room temperature for 20-30 h, and cleaning and drying the anastomosis nail by using deionized water after the reaction is finished;
step four, respectively dissolving hydrazine hydrate, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in water to prepare a mixed solution, soaking the anastomosis nail treated in the step three in the mixed solution, reacting at room temperature for 20-30 h, and cleaning and drying the anastomosis nail by using deionized water after the reaction is finished to obtain the surface hydrazide-based anastomosis nail;
and step five, soaking the anastomosis nail with the surface hydrazide group in an ethanol solution containing dexamethasone, reacting for 20-30 h at 60-70 ℃, washing with ethanol after the reaction, and drying to obtain the anastomosis nail with the anti-inflammatory function.
4. The method for preparing a staple having an anti-inflammatory function according to claim 3, wherein: in the fifth step, the ethanol solution containing dexamethasone is specifically prepared as follows: 20-100 g of dexamethasone is added into each 10mL of ethanol solution.
5. The method for preparing a staple having an anti-inflammatory function according to claim 3, wherein: in the third step, the molar ratio of oxalic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide prepared is 1: (0.8-1.2): (0.8 to 1.2).
6. The method for preparing a staple having an anti-inflammatory function according to claim 3, wherein: in the fourth step, the molar ratio of hydrazine hydrate, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide is 1: (0.8-1.2): (0.8 to 1.2).
7. The method for preparing a staple having an anti-inflammatory function according to claim 3, wherein: in the first step, the processing power of the plasma equipment is 1-5 kw, the processing time is 10-30 min, the processing temperature is 0-40 ℃, and oxygen is used as the processing atmosphere to perform processing under the vacuum condition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011083694.1A CN112190772B (en) | 2020-10-12 | 2020-10-12 | Anastomosis nail with anti-inflammation function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011083694.1A CN112190772B (en) | 2020-10-12 | 2020-10-12 | Anastomosis nail with anti-inflammation function and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112190772A true CN112190772A (en) | 2021-01-08 |
| CN112190772B CN112190772B (en) | 2021-10-29 |
Family
ID=74014328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011083694.1A Active CN112190772B (en) | 2020-10-12 | 2020-10-12 | Anastomosis nail with anti-inflammation function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112190772B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060286140A1 (en) * | 2003-09-15 | 2006-12-21 | Eric Wickstrom | Implants with attached silylated therapeutic agents |
| CN102631714A (en) * | 2012-04-20 | 2012-08-15 | 王学凡 | Titanium nail |
| CN102861364A (en) * | 2012-10-16 | 2013-01-09 | 天津市第三中心医院 | Preparation method and application of dexamethasone sodium phosphate-sodium alga acid composite slow-release coating |
| CN103239265A (en) * | 2013-05-10 | 2013-08-14 | 杭州铭众生物科技有限公司 | Anastomat for gastrointestinal tract anastomosis surgery and production method thereof |
| CN108261597A (en) * | 2018-01-22 | 2018-07-10 | 上海长海医院 | A kind of T-shaped trachea cannula with the anti-hyperblastosis of antibacterial |
-
2020
- 2020-10-12 CN CN202011083694.1A patent/CN112190772B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060286140A1 (en) * | 2003-09-15 | 2006-12-21 | Eric Wickstrom | Implants with attached silylated therapeutic agents |
| CN102631714A (en) * | 2012-04-20 | 2012-08-15 | 王学凡 | Titanium nail |
| CN102861364A (en) * | 2012-10-16 | 2013-01-09 | 天津市第三中心医院 | Preparation method and application of dexamethasone sodium phosphate-sodium alga acid composite slow-release coating |
| CN103239265A (en) * | 2013-05-10 | 2013-08-14 | 杭州铭众生物科技有限公司 | Anastomat for gastrointestinal tract anastomosis surgery and production method thereof |
| CN108261597A (en) * | 2018-01-22 | 2018-07-10 | 上海长海医院 | A kind of T-shaped trachea cannula with the anti-hyperblastosis of antibacterial |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112190772B (en) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9962451B2 (en) | Active principle for mitigating undesired medical conditions | |
| US6627749B1 (en) | Powdered oxidized cellulose | |
| EP0063604A1 (en) | Mucous membrane-adhering film preparation and process for its preparation | |
| JP2003507082A (en) | A new method to adjust surface modifying substances | |
| EP0564722A1 (en) | Lathyrogenic agents and apparatus for the treatment of fibrotic lesions | |
| CN103189035A (en) | Anti-adhesion alginate barrier of variable absorbance | |
| CN114404649B (en) | Hydrogel with pH/glucose dual-response metformin release function and preparation method and application thereof | |
| CN109453420B (en) | Hemostatic composition, preparation method and application thereof | |
| JP2002507582A (en) | Iron-dextran compound for use as a component of a therapeutic composition for the prevention or treatment of iron deficiency, a method for producing said iron-dextran compound, and use of said compound for producing a parenterally administrable therapeutic composition | |
| CN112898598A (en) | Tissue adhesion hydrogel and preparation method and application thereof | |
| Konturek et al. | Cytoprotective and ulcer healing properties of prostaglandin E2, colloidal bismuth and sucralfate in rats | |
| CN112190772B (en) | Anastomosis nail with anti-inflammation function and preparation method thereof | |
| JPH0484965A (en) | Soluble hemostaic fabric | |
| TW201124142A (en) | Hypersulfated disaccharide formulations | |
| JPH06503319A (en) | Cell proliferation matrix and its use | |
| CN105963771A (en) | Medical dressing with bioactive components and method for preparing medical dressing | |
| CN115536919B (en) | Modified chitosan adhesive hydrogel and preparation method and application thereof | |
| CN114921105B (en) | Electric response type silk fibroin material, preparation method thereof and electric response type silk fibroin microneedle | |
| WO1998007445A1 (en) | Preventive/remedy for frequent urination and urinary incontinence | |
| JPH0566148B2 (en) | ||
| CN113967192A (en) | Pharmaceutical composition for accelerating wound healing, preparation method and application thereof | |
| CN113512132A (en) | Quick hemostatic hydrogel and preparation method thereof | |
| CN113499479A (en) | Preparation method of modified biological material and obtained modified biological material | |
| JPS621731B2 (en) | ||
| CN106924818B (en) | Drug-loaded gel and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210108 Assignee: Jiangsu Maxon automation equipment Co.,Ltd. Assignor: HUAIYIN INSTITUTE OF TECHNOLOGY Contract record no.: X2021980014115 Denomination of invention: Anastomotic nail with anti-inflammatory function and its preparation method Granted publication date: 20211029 License type: Common License Record date: 20211209 |